Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory study of one intramuscular dose of MF59-adjuvanted Focetria pandemic H1N1 vaccine in healthy adults
2009-017141-58Phase 4Terminated
- Sponsor
- Opera Bioscience
- Start
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in influenza A virus infection (H1N1), sponsored by Opera Bioscience. Primary endpoints: Cell-mediated immunity response, Antibody response to H1N1sw and 1 more. Started Nov 2009; status: terminated.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-017141-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017141-58.